Sonoma Pharmaceuticals (Formerly Known As Oculus Innovative Sciences, Inc.)
1135 North McDowell Boulevard
Petaluma
California
94954
United States
Tel: 707-782-0792
Fax: 707-782-0705
Website: https://sonomapharma.com/
310 articles about Sonoma Pharmaceuticals (Formerly Known As Oculus Innovative Sciences, Inc.)
-
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
4/9/2024
Sonoma Pharmaceuticals, Inc. today announced the expansion of its Microcyn Negative-Pressure Wound Therapy (NPWT) Solution products in the United States.
-
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
4/4/2024
Sonoma Pharmaceuticals, Inc. reported a recent publication in the journal Neurourology and Urodynamics highlighting the potential for Microdox in the management of urinary tract infections.
-
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
3/28/2024
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced that it will be presenting at two upcoming investor conferences in Denver and New York.
-
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
3/27/2024
Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid products for a wide range of applications, including wound care and dermatological conditions, highlights the safety advantages of its Microcyn technology products in response to concerns related to benzoyl peroxide, a common ingredient in dermatology products.
-
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results
2/8/2024
Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA) today announced financial results for its third fiscal quarter and nine months ended December 31, 2023.
-
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
1/9/2024
NovaBay Pharmaceuticals, Inc. and Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced an agreement for the sale and marketing of Avenova branded products by Sonoma in the European Union.
-
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
11/13/2023
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its second fiscal quarter ended September 30, 2023.
-
Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference
11/3/2023
Sonoma Pharmaceuticals, Inc. announced the U.S. launch of its intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures.
-
Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common Stock
10/26/2023
Sonoma Pharmaceuticals, Inc. today announced the pricing of its public offering of 8,500,000 shares of common stock at a price of $0.20 per share.
-
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
8/15/2023
Sonoma Pharmaceuticals, Inc. announced that Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel has received the National Eczema Association Seal of Acceptance™.
-
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial Results
8/10/2023
Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended June 30, 2023.
-
Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board
8/3/2023
Sonoma Pharmaceuticals, Inc. today announced the appointment of Dr. Hye Jin Chung MD, MMSc, Assistant Professor of Dermatology at Harvard Medical School in Boston and practicing dermatologist at Beth Israel Deaconess Medical Center, to the company's Scientific Advisory Board.
-
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2023 Financial Results
6/22/2023
Sonoma Pharmaceuticals, Inc. today announced financial results for fiscal year 2023 and the fourth quarter ended March 31, 2023.
-
Sonoma Pharmaceuticals Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union
6/8/2023
Sonoma Pharmaceuticals, Inc. announced a new application for intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures.
-
Sonoma Pharmaceuticals Introduces Podiacyn, an All Natural, Over-the-Counter Podiatry Product for Daily Foot Care
4/11/2023
Sonoma Pharmaceuticals, Inc. today announced the launch of Podiacyn TM Advanced Everyday Foot Care direct to consumers for over-the-counter use in the United States.
-
Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI North America Conference in Philadelphia
3/28/2023
Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA) announced that it will be exhibiting at the CPHI North America Conference in Philadelphia, Pennsylvania April 25-27, 2023.
-
Sonoma Pharmaceuticals and MicroSafe Group Announce New EPA Claims and Green Seal Certification for Nanocyn(R) Hospital-Grade Disinfectant
3/2/2023
Sonoma Pharmaceuticals, Inc. and its partner, the MicroSafe Group DMCC, are excited to announce that Nanocyn hospital-grade disinfectant has received additional claims from the U.S. Environmental Protection Agency (EPA) for effective use against Methicillin Resistant Staphylococcus Aureus (MRSA), Salmonella, Norovirus, Poliovirus, and as a fungicide
-
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea
1/31/2023
Sonoma Pharmaceuticals, Inc. today announced that it has entered into a distribution agreement with Daewoong Pharmaceutical Co., Ltd. for the marketing and distribution of Primocyn TM Skin Solution products.
-
Sonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx Products
1/25/2023
Sonoma Pharmaceuticals, Inc. today announced that Microcyn Rx products have received a Distribution and Pricing Agreement (DAPA) for distribution by the Defense Logistics Agency (DLA).
-
Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas
1/4/2023
Sonoma Pharmaceuticals, Inc. today announced that it has launched a line of office dispense products exclusively for skin care professionals.